ST Renfu announced that Yichang Renfu, a holding subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” for midazolam nasal spray approved and issued by the State Drug Administration and agreed to conduct clinical trials. This drug is a class 3 chemical drug intended for acute treatment of cluster seizures in people aged 12 and above with epilepsy. Currently, it is not marketed domestically. Yichang Renfu has invested a total of about 7.3 million yuan in R&D in this project, and work related to clinical research will be initiated in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.